Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for the Treatment of Malaria in Western Cambodia.

Abstract

This single-arm trial (n = 104) in western Cambodia showed high efficacy for 3-day treatment with pyronaridine-artesunate plus single-dose primaquine in Plasmodium falciparum malaria. Day 42 PCR-adjusted adequate clinical and parasitological response (ACPR) was 98.3% (58/59) (95% confidence interval [CI], 90.9 to 100.0) in Trapeng Chau in Kampong Speu and 100% (41/41) (95% CI, 91.4 to 100) in Veal Veng in Pursat; 80.6% (83/103) of the patients had P. falciparum with drug resistance molecular markers. For Plasmodium vivax malaria, pyronaridine-artesunate day 28 ACPR was 98.3% (59/60) (95% CI, 91.1 to 100) and 100% (60/60) (95% CI, 94.0 to 100), respectively. (This study is registered in the Australian New Zealand Clinical Trials Registry [ANZCTR] under reference no. ACTRN12618001999224.).

• Authors: Rithea Leang, Nimol Khim, Huch Chea, Rekol Huy, Melissa Mairet-Khedim, Denis Mey Bouth, Maria Dorina Bustos, Pascal Ringwald, Benoit Witkowski
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 63 Issue 10 (10 2019) ISSN: 1098-6596 [Electronic] United States
• PMID: 31358594 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2019 American Society for Microbiology.

Chemical References

• Antimalarials
• Naphthyridines
• Artesunate
• Primaquine
• pyronaridine

Topics

• Adolescent
• Adult
• Antimalarials (adverse effects, therapeutic use)
• Artesunate (adverse effects, therapeutic use)
• Cambodia
• Child
• Drug Resistance
• Female
• Humans
• Malaria (drug therapy)
• Male
• Middle Aged
• Naphthyridines (adverse effects, therapeutic use)
• Plasmodium vivax (drug effects, pathogenicity)
• Primaquine (adverse effects, therapeutic use)
• Young Adult